Arvinas saw the highest growth of 1.79% in patent filings and 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.37% and grants by 0.79%. GlobalData’s DataBook provides a comprehensive analysis of Arvinas‘s patent filings and grants. Buy the databook here.
Arvinas has been focused on protecting inventions in United States(US) with 12 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 30% filings and 67% grants. The United States(US), World Intellectual Property Organization(WIPO), Australia(AU), and Israel(IL) patent Office are among the top ten patent offices where Arvinas is filings its patents. Among the top granted patent authorities, Arvinas has 67% of its grants in United States(US) and 11% in China(CN).
Roche could be the strongest competitor for Arvinas
Patents related to rare diseases lead Arvinas's portfolio
Arvinas has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
Prostate cancer related patents lead Arvinas portfolio followed by breast cancer, and lymphoma
Arvinas has highest number of patents in prostate cancer followed by breast cancer, lymphoma, ovarian cancer, and non-small cell lung cancer. For prostate cancer, nearly 7% of patents were filed and 5% of patents were granted in Q2 2024.
For comprehensive analysis of Arvinas's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.